Humacyte Awarded $3.4 Million Contract Award from the U.S. Defense Department

Humacyte, an innovator in biotechnology and regenerative medicine, announced today that the company has received a Broad Agency Announcement (BAA) contract award of $3.4 million from the U.S. Department of Defense (DoD). The funding will help support the addition of clinical sites for Humacyte’s Phase II vascular trauma trial in the U.S. The trial is a study of Humacyte’s investigational human acellular vessel (HAV), or HUMACYL®, which treats patients with traumatic vascular injuries from violent civilian or military events, such as automobile crashes, industrial accidents, or war injuries.

The DoD is America’s oldest and largest government agency, with more than 1.3 million men and women on active duty and 742,000 civilian personnel. The DoD U.S. Army’s Medical Unit recently began working with Humacyte and other partners in the biomedical space to find solutions for injured warfighters and to advance the agency’s mission to provide military forces with support to deter war and to protect national security.